4538
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Fuso Pharmaceutical Industries, Ltd. is a pharmaceutical company that manufactures and sells medical drugs and medical machinery. Its primary business segment focuses on the production of injectable solutions, including intravenous fluids and dialysis agents for artificial kidneys, as well as the provision of contract manufacturing services for other pharmaceutical products. The company also operates a real estate segment for property leasing. Fuso Pharmaceutical Industries serves the healthcare sector by supplying essential medical supplies and equipment to the market.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage fuso-pharm.co.jp
Sector Healthcare IR page fuso-pharm.co.jp
Tags
intravenous fluids, dialysis agents, injectable solutions, medical machinery, contract manufacturing, real estate leasing
Press page fuso-pharm.co.jp/news

Metrics

Valuation  
Market cap ¥ 20.783B
Market cap (USD) $ 129.896M
P/E 8.45
PEG 1.08
P/BV 0.57
P/S 0.33
P/OCF 3.03
P/FCF 4.17
Dividend yield 4.1%
Turnover / mcap —
Returns  
ROE 5.9%
ROI 3.2%
ROIC 3.5%
Profit margin 3.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 7.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 62.307B 60.563B 55.407B 51.015B 49.632B 49.251B 46.902B 46.074B 45.9B 46.782B 45.752B 47.042B 49.098B 48.612B
Net profit 2.011B -3.288B 1.377B 1.605B 1.483B 1.607B 707M 894M 970M 861M 10M 340M 1.979B 4.871B
Free cash flow -7.883B -6.403B -2.961B 1.279B 2.011B 2.02B 3.224B -267M -297M 38M -3.195B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 2.356K 2.208K 2.208K 1.995K 2.181K 2.546K 2.095K 2.529K 2.828K 2.809K 2.606K 3.112K 3.63K 4.143K
Price performance 12m 0.07 0 0.11 -0.09 -0.14 0.22 -0.17 -0.11 0.01 0.08 -0.16 -0.14 -0.12 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 21.4B 22B 22.1B 20.4B 239M 302M 21.7B 24.3B 26.5B 26.9B
↳ YoY growth +3.5% +2.9% +0.4% -7.5% -98.8% +26.4% +7,099.0% +11.9% +8.9% +1.5%
↳ 5y CAGR -59.0% -57.3% -0.2% +2.0% +5.4% +157.2%
Borrowings, current (JPY) 6.02B 6.61B 6.54B 6.51B 6.2B 5.94B 5.66B 5.7B 18.8B 26.6B
Borrowings, non-current (JPY) 8.29B 8.91B 9.39B 8.25B 6.64B 5.76B 5.75B 7.02B 2.46B 1.86B
Bonds payable (JPY) 114M 38M — — — — — — — —
Lease liabilities (JPY) 7M 3M 4M 1M 2M 1M — — — —
Cash and deposits (JPY) 4.95B 5.46B 5.73B 7.27B 7.07B 7.35B 8.01B 5.12B 6.26B 4.85B
Intangible assets (JPY) 509M 1.01B 753M 518M 323M 453M 329M 600M 1.51B 1.35B
Net debt (borrowings + leases - cash) (JPY) 9.37B 10.1B 10.2B 7.48B 5.76B 4.35B 3.4B 7.6B 15B 23.6B
Cash flow detail
Operating cash flow (JPY) 1.88B 1.42B 2.05B 5.73B 3.23B 3.5B 2.85B 627M -3.31B -6.22B
Purchases of property, plant and equipment (JPY) -1.84B -961M -2.3B -2.49B -1.18B -1.41B -1.55B -3.25B -2.12B -1.27B
Purchases of intangible assets (JPY) -318M -756M -22M -10M -28M -79M -28M -343M -976M —
Change in receivables (cash effect) (JPY) -725M -620M -84M 1.66B -983M 231M -588M -2.59B -2.16B —
Change in inventories (cash effect) (JPY) -731M 96M -654M 280M -712M 213M -1.94B -1.75B -739M —
Change in payables (cash effect) (JPY) 501M -529M 416M 634M -325M 715M 1.45B 1.75B -7.8B —
Dividends paid (cash effect) (JPY) -717M -706M -700M -613M -525M -525M -525M -645M -638M —
Share buybacks (cash effect) (JPY) -282M -427M -6M -2M -4M -2M -3M -652M -4M —
Interest paid (cash effect) (JPY) -225M -217M -229M -234M -195M -176M -166M -170M -143M —
Income taxes paid (cash effect) (JPY) -99M -584M -348M -374M -190M -979M -239M -578M -374M —
Operating cash flow before change in receivables (JPY) 2.6B 2.04B 2.14B 4.07B 4.21B 3.27B 3.44B 3.21B -1.14B —
Free cash flow (OCF - PPE - intangibles) (JPY) 38M -297M -267M 3.22B 2.02B 2.01B 1.28B -2.96B -6.4B —
Income detail
Research and development expense (JPY) 2.26B 2.01B 1.76B 1.41B 1.46B 1.44B 1.35B 1.47B 1.72B 2.01B
↳ 5y CAGR -7.9% -8.6% -7.6% -3.6% +4.0% +6.6%
Provision for credit losses (JPY) — — — — 216M -216M — — — —
Credit cost ratio (credit losses / average receivables) (%) — — — — 2.1% 79.9% — — — —
Reported Jun 26, 2018 Jun 26, 2018 Jun 26, 2020 Jun 29, 2021 Jun 29, 2022 Jun 29, 2023 Jun 25, 2024 Jun 24, 2025 Jun 23, 2026 Nov 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

2027年3月期 第2四半期決算補足説明資料 Bull 3 Bear 0 Results

Prompts

Fuso Pharmaceutical Industries, Ltd. (ticker 4538), listed in Japan.

ETFs Holding Fuso Pharmaceutical Industries, Ltd.

ETF Weight in ETF Shares Market value As of
DISV 0.00% 14,200 $ 193.33K Nov 12, 2026
DFIS 0.00% 12,200 $ 166.1K Nov 12, 2026
DFIC 0.00% 6,300 $ 85.773K Nov 12, 2026
DFAX 0.00% 4,400 $ 59.905K Nov 12, 2026
DFAI 0.00% 2,200 $ 29.952K Nov 12, 2026
AVDS 0.00% 100 $ 1,371.60 Nov 16, 2026